PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 1 - 7 of 7 results
News
|
Feb. 15, 2007
|
2 min read
News
|
March 3, 2017
|
3 min read
News
|
Aug. 11, 2014
|
2 min read
News
|
March 2, 2009
|
1 min read
News
|
Aug. 11, 2014
|
1 min read
News
|
Dec. 28, 2007
|
1 min read
News
|
Aug. 1, 2008
|
1 min read